Protagonist reports MIMRYLO FDA approval, Q3 2026 results, PN-881 Phase 2b plan
FDA approval of MIMRYLO triggered $275 million in payments to Protagonist, and the company plans a Phase 2b psoriasis study of PN-881 for early Q1 2027.
SEC filing
1 story
FDA approval of MIMRYLO triggered $275 million in payments to Protagonist, and the company plans a Phase 2b psoriasis study of PN-881 for early Q1 2027.
SEC filing